zipalertinib is under development for the treatment of non-small cell lung cancer. The drug candidate acts by targeting epidermal growth factor receptor (EGFR) with Exon 20 insertions. It is ...

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows ...